Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET tracer could spot dangerous plaques before they cause strokes

NCT ID NCT01608516

Knowledge-focused Sponsor: University of Lausanne Hospitals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study compares a new imaging tracer, 68Ga-NODAGA-RGD, with standard methods (FDG-PET, MRI, ultrasound) to detect inflamed plaques in the carotid arteries. Twenty people scheduled for plaque-removal surgery will receive the tracer and undergo scans. The goal is to see which technique best identifies unstable, inflammation-prone plaques, using tissue analysis after surgery as the gold standard.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
68Ga-NODAGA-RGD, a radioactive tracer for PET/CT imaging
What this could lead to
If successful, this imaging method could help identify dangerous artery plaques earlier, potentially preventing strokes.
What could go wrong
This is a small, early-phase study focused on imaging accuracy, not treatment. The tracer may not prove superior to existing methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2012

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age \<= 85 years * Karnofsky \>= 80% * patient with indication ofr carotid endarterectomy * signed consent form Exclusion Criteria: * indication for surgery other than endarterectomy \<14 days * contraindication to surgery * contraindication to MRI * contraindication to gadolinium injection (stage 4/5 kidney insufficiency, GFR\<30ml/min/1.73m2) * pregnancy, breastfeeding * lack of discernment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atheromatous plaques are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis carotid artery disorder Inflammation inflammatory disease Plaque, Atherosclerotic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atheromatous plaques Carotid artery diseases Inflammation

Contacts and locations

Locations

  • Centre Hospitalier Universitaire Vaudois

    Lausanne, Canton of Vaud, 1011, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.